ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Trial record **1 of 1** for: TMC435-TIDP16-C205
Previous Study | Return to List | Next Study

A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment (PILLAR)

This study has been completed.

Sponsor:
Tibotec Pharmaceuticals, Ireland

Information provided by (Responsible Party):
Tibotec Pharmaceuticals, Ireland

ClinicalTrials.gov Identifier:
NCT00882908

First received: April 16, 2009
Last updated: May 19, 2014
Last verified: May 2014
History of Changes

Full Text View | Tabular View | Study Results | Disclaimer | How to Read a Study Record

Results First Received: December 18, 2013

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor); Primary Purpose: Treatment
Condition:	Hepatitis C
Interventions:	Drug: TMC435 Drug: Ribavirin (R) Drug: PegIFNα-2a (P) Drug: Placebo

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study was conducted at 79 sites in 13 countries: Australia, New Zealand, Canada, Austria, Belgium, Germany, Spain, France, Poland, Russia, Norway, Denmark, and the United States. Approximately 68% of participants were enrolled in Europe, 21% in North America, and 11% in Australia/New Zealand.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
In total, 506 participants were screened; 388 participants were randomized of whom 386 participants started treatment. Two randomized participants did not start treatment due to withdrawal of consent.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.

TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Participant Flow: Overall Study

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	Placebo 24 Wks + PR48
STARTED	78	75	77	79	77
COMPLETED	75	69	70	72	71
NOT COMPLETED	3	6	7	7	6
Adverse Event	0	0	1	0	1
Lost to Follow-up	3	5	3	1	2
Protocol Violation	0	1	0	0	0
Withdrawal by Subject	0	0	3	5	2
Subject reached a virologic endpoint	0	0	0	0	1
Study terminated in error	0	0	0	1	0

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.

TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.
Total	Total of all reporting groups

Baseline Measures

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	Placebo 24 Wks + PR48	Total
Number of Participants [units: participants]	**78**	**75**	**77**	**79**	**77**	**386**
Age [units: years] Median (Full Range)	**47 (19 to 66)**	**46 (18 to 67)**	**47 (18 to 69)**	**47 (18 to 69)**	**45 (21 to 67)**	**46.5 (18 to 69)**
Gender [units: participants]						
Female	**38**	**28**	**34**	**35**	**38**	**173**
Male	**40**	**47**	**43**	**44**	**39**	**213**
Region of Enrollment [units: participants]						
Asia Pacific	**9**	**9**	**7**	**13**	**4**	**42**
Europe	**52**	**52**	**56**	**44**	**58**	**262**
North-America	**17**	**14**	**14**	**22**	**15**	**82**

Outcome Measures

Hide All Outcome Measures

1. Primary: The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72) [Time Frame: Week 72]

Measure Type	Primary
Measure Title	The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
Measure Description	The table below shows the percentage of participants in each treatment group who achieved a SVRW72, defined as the percentage of participants with undetectable plasma Hepatitis C virus ribonucleic acid levels at end of treatment (EOT) and at Week 72.
Time Frame	Week 72
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description

TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	Placebo 24 Wks + PR48
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72) [units: Percentage of participants]	**80.8**	**70.7**	**77.9**	**84.8**	**64.9**

Statistical Analysis 1 for The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)

Groups [1]	TMC435 75 mg 12 Wks + PR 24/48 vs. TMC435 75 mg 24 Wks + PR 24/48 vs. Placebo 24 Wks + PR48
Method [2]	Regression, Logistic
P Value [3]	0.051
Difference in proportions of SVRW72 [4]	13.0
97.5% Confidence Interval	-1.9 to 28.0

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	TMC435 75 mg 12 and 24 week treatment groups were pooled and the percentage of participants acheiving SVRW72 were compared with the percentage of participants acheiving SVRW72 in the placebo treatment group.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.
[4]	Other relevant estimation information:
	Difference in percentages of participants in the TMC435 75mg and placebo groups with undetectable plasma Hepatitis C virus ribonucleic acid levels at end of treatment (EOT) and at Week 72 estimated from the logistic regression model.

Statistical Analysis 2 for The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)

Groups [1]	TMC435 150 mg 12 Wks + PR 24/48 vs. TMC435 150 mg 24 Wks + PR 24/48 vs. Placebo 24 Wks + PR48
Method [2]	Regression, Logistic
P Value [3]	0.004
Difference in proportions of SVRW72 [4]	18.9
97.5% Confidence Interval	4.4 to 33.5

[1]	Additional details about the analysis, such as null hypothesis and power calculation:
	TMC/PR 150 mg 12 and 24 week treatment groups were pooled and the percentage of participants achieving SVRW72 was compared the percentage of participants achieving SVRW72 in the placebo treatment group.
[2]	Other relevant method information, such as adjustments or degrees of freedom:
	No text entered.
[3]	Additional information, such as whether or not the p-value is adjusted for multiple comparisons and the a priori threshold for statistical significance:
	No text entered.
[4]	Other relevant estimation information:
	Difference in percentages of participants in the TMC435 150mg and placebo groups with undetectable plasma Hepatitis C virus ribonucleic acid levels at end of treatment (EOT) and at Week 72 estimated from the logistic regression model.

2. Secondary: The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up [Time Frame: Weeks, 2, 4, 8, 12, 24, 36, 48, 60, 72, and at EOT (up to Week 24 or 48)]

Measure Type	Secondary
Measure Title	The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up
Measure Description	The table below shows the percentage of participants in each treatment group who achieved plasma HCV RNA levels of less than 25 IU/mL undetectable at selected time points during treatment, follow-up, and at end of treatment (EOT).
Time Frame	Weeks, 2, 4, 8, 12, 24, 36, 48, 60, 72, and at EOT (up to Week 24 or 48)
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at

	Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	Placebo 24 Wks + PR48
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up [units: Percentage of participants]					
Week 2	**39.7**	**30.7**	**23.4**	**39.2**	**2.6**
Week 4	**75.6**	**68.0**	**75.3**	**74.7**	**5.2**
Week 8	**87.2**	**90.7**	**92.2**	**93.7**	**26.0**
Week 12	**91.0**	**93.3**	**93.5**	**94.9**	**55.8**
Week 24	**92.3**	**93.3**	**84.4**	**87.3**	**77.9**
Week 36	**85.9**	**81.3**	**81.8**	**84.8**	**76.6**
Week 48	**79.5**	**77.3**	**79.2**	**82.3**	**74.0**
Week 60	**79.5**	**68.0**	**75.3**	**83.5**	**63.6**
Week 72	**79.5**	**70.7**	**77.9**	**82.3**	**64.9**
EOT (up to Week 24 or 48)	**92.3**	**97.3**	**92.2**	**93.7**	**79.2**

No statistical analysis provided for The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up

3. Secondary: The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up [Time Frame: Weeks 2, 4, 8, 12, 24, 36, 48, 60, 72, and at EOT (up to Week 24 or 48)]

Measure Type	Secondary
Measure Title	The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up
Measure Description	The table below shows the percentage of participants in each treatment group who achieved plasma levels of HCV RNA less than 25 IU/mL detectable or undetectable at selected time points during treatment, follow-up, and at end of treatment (EOT).
Time Frame	Weeks 2, 4, 8, 12, 24, 36, 48, 60, 72, and at EOT (up to Week 24 or 48)
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	Placebo 24 Wks + PR48
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up [units: Percentage of participants]					
Week 2	**65.4**	**66.7**	**75.3**	**78.5**	**5.2**
Week 4	**85.9**	**88.0**	**90.9**	**91.1**	**15.6**
Week 8	**93.6**	**94.7**	**93.5**	**93.7**	**49.4**
Week 12	**93.6**	**94.7**	**96.1**	**94.9**	**66.2**
Week 24	**92.3**	**93.3**	**84.4**	**89.9**	**80.5**
Week 36	**85.9**	**81.3**	**81.8**	**84.8**	**79.2**
Week 48	**79.5**	**77.3**	**79.2**	**82.3**	**75.3**
Week 60	**79.5**	**68.0**	**75.3**	**83.5**	**64.9**
Week 72	**79.5**	**70.7**	**77.9**	**83.5**	**64.9**
EOT (up to Week 24 or 48)	**93.6**	**97.3**	**92.2**	**96.2**	**83.1**

No statistical analysis provided for The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up

4. Secondary: The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment [Time Frame: Baseline (Day 1) and Weeks, 2, 4, 8, and 12]

Measure Type	Secondary
Measure Title	The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment
Measure Description	The table below shows the percentage of participants in each treatment group who achieved plasma levels of HCV RNA greater than or equal to 2 log10 drop from Baseline at selected time points during treatment.
Time Frame	Baseline (Day 1) and Weeks, 2, 4, 8, and 12
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment [units: Percentage of participants]					
Week 2	**93.6**	**98.7**	**97.4**	**98.7**	**40.3**
Week 4	**94.9**	**98.7**	**97.4**	**93.7**	**71.4**
Week 8	**97.4**	**97.3**	**97.4**	**94.9**	**84.4**
Week 12	**97.4**	**96.0**	**96.1**	**96.2**	**89.6**

No statistical analysis provided for The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment

5. Secondary: The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24) [Time Frame: Week 48 or 72]

Measure Type	Secondary
Measure Title	The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
Measure Description	The table below shows the percentage of participants in each treatment group who achieved a SVR24, defined as having undetectable plasma Hepatitis C virus ribonucleic acid levels at the end of treatment (EOT) and 24 weeks after the EOT.
Time Frame	Week 48 or 72
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24) [units: Percentage of participants]	**82.1**	**74.7**	**80.5**	**86.1**	**64.9**

No statistical analysis provided for The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)

6. Secondary: The Percentage of Participants Achieving a Rapid Virologic Response (RVR) [Time Frame: Week 4]

Measure Type	Secondary
Measure Title	The Percentage of Participants Achieving a Rapid Virologic Response (RVR)
Measure Description	The table below shows the percentage of participants in each treatment group who achieved a RVR, defined as having undetectable plasma Hepatitis C virus ribonucleic acid levels after receiving 4 weeks of treatment.
Time Frame	Week 4
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving a Rapid Virologic Response (RVR) [units: Percentage of participants]	**75.6**	**68.0**	**75.3**	**74.7**	**5.2**

No statistical analysis provided for The Percentage of Participants Achieving a Rapid Virologic Response (RVR)

7. Secondary: The Percentage of Participants Achieving an Early Virologic Response (EVR) [Time Frame: Baseline (Day 1) and Week 12]

Measure Type	Secondary

Measure Title	The Percentage of Participants Achieving an Early Virologic Response (EVR)
Measure Description	The table below shows the percentage of participants who achieved an EVR, defined as having a change from baseline in plasma Hepatitis C virus ribonucleic acid of 2 log10 at Week 12.
Time Frame	Baseline (Day 1) and Week 12
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving an Early Virologic Response (EVR) [units: Percentage of participants]	**97.4**	**96.0**	**96.1**	**96.2**	**89.6**

No statistical analysis provided for The Percentage of Participants Achieving an Early Virologic Response (EVR)

8. Secondary: The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR) [Time Frame: Week 12]

Measure Type	Secondary
Measure Title	The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)
Measure Description	The table below shows the percentage of participants in each treatment group who had a cEVR, defined as having undetectable plasma Hepatitis C Virus ribonucleic acid levels at Week 12.
Time Frame	Week 12

Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR) [units: Percentage of participants]	**91.0**	**93.3**	**93.5**	**94.9**	**55.8**

No statistical analysis provided for The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)

9. Secondary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) [Time Frame: Up to Week 36 or 52]

Measure Type	Secondary
Measure Title	The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
Measure Description	The table below shows the percentage of participants who achieved undetectable plasma Hepatitis C virus ribonucleic acid levels at the end of treatment (EOT) and 12 Weeks after the EOT.
Time Frame	Up to Week 36 or 52
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) [units: Percentage of participants]	**83.3**	**76.0**	**80.5**	**86.1**	**66.2**

No statistical analysis provided for The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)

10. Secondary: Number of Participants With Viral Breakthrough [Time Frame: Week 24 or 48]

Measure Type	Secondary
Measure Title	Number of Participants With Viral Breakthrough
Measure Description	The table below shows the number of participants in each treatment group who experienced viral breakthrough during the TMC435 treatment period of the study, defined as a confirmed increase of more than 1 log10 IU/mL in plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) level from the lowest level reached or a confirmed value of plasma HCV RNA more than 100 IU/mL in participants whose plasma HCV RNA level had previously been below the limit of quantification (less than 25 IU/mL detectable or undetectable).
Time Frame	Week 24 or 48
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or

another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
Number of Participants With Viral Breakthrough [units: Participants]	**5**	**2**	**6**	**2**	**4**

No statistical analysis provided for Number of Participants With Viral Breakthrough

11. Secondary: The Number of Participants With Viral Relapse [Time Frame: Up to Week 72]

Measure Type	Secondary
Measure Title	The Number of Participants With Viral Relapse
Measure Description	The table below shows the number of participants who experienced viral relapse, defined as a confirmed detectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) level during the follow-up period in participants with undetectable plasma HCV RNA (less than 25 IU/mL undetectable) at the end of treatment.
Time Frame	Up to Week 72
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	Placebo 24 Wks + PR48
Number of Participants Analyzed [units: participants]	**78**	**75**	**77**	**79**	**77**
The Number of Participants With Viral Relapse [units: Participants]	**8**	**14**	**6**	**6**	**11**

No statistical analysis provided for The Number of Participants With Viral Relapse

12. Secondary: The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT) [Time Frame: Baseline (Day 1) up to Week 24 or 48]

Measure Type	Secondary
Measure Title	The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)
Measure Description	The table below shows the number of participants with abnormal ALT levels at Baseline who achieved ALT levels within the normal range at the EOT.
Time Frame	Baseline (Day 1) up to Week 24 or 48
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
The intent-to treat population (defined as those participants who received at least 1 dose of study medication) was used for all efficacy and safety analyses.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice

	daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
All TMC435 Treatment Groups	Participants in all 4 TMC435 treatment groups combined.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48	All TMC435 Treatment Groups
Number of Participants Analyzed [units: participants]	**43**	**45**	**48**	**43**	**179**
The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT) [units: Participants]	**39**	**37**	**39**	**35**	**150**

No statistical analysis provided for The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)

13. Secondary: Plasma Concentrations of TMC435 [Time Frame: Two random blood samples taken at least 2 hours apart at Weeks 2, 4, 8, 12, 16, and 24]

Measure Type	Secondary
Measure Title	Plasma Concentrations of TMC435
Measure Description	The table below shows median (range) predose plasma concentration (C0h) values and median (range) average steady-state plasma concentration (Css,av) values for participants in each of the 4 TMC435 treatment groups.
Time Frame	Two random blood samples taken at least 2 hours apart at Weeks 2, 4, 8, 12, 16, and 24
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who received at least 1 dose of study medication with at least 1 post-baseline pharmacokinetic (PK) assessment were included in the PK analysis population.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.

TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	TMC435 75 mg 24 Wks + PR 24/48	TMC435 150 mg 12 Wks + PR 24/48	TMC435 150 mg 24 Wks + PR 24/48
Number of Participants Analyzed [units: participants]	**77**	**75**	**77**	**78**
Plasma Concentrations of TMC435 [units: ng/mL] Median (Full Range)				
Coh	**240.9 (0 to 1927)**	**213.6 (40 to 2124)**	**1123.3 (91 to 13771)**	**1176.7 (0 to 9875)**
Css, av	**413.6 (6 to 2091)**	**374.0 (151 to 2385)**	**1661.8 (123 to 15868)**	**1501.6 (47 to 11648)**

No statistical analysis provided for Plasma Concentrations of TMC435

14. Secondary: Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435 [Time Frame: Two random blood samples taken at least 2 hours apart at Weeks 2, 4, 8, 12, 16, and 24]

Measure Type	Secondary
Measure Title	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435
Measure Description	The table below shows the median (range) AUC24h values for TMC435 for participants in each of the 4 TMC435 treatment groups. Two blood samples taken at least 2 hours apart from each other for determination of TMC435 plasma pharmacokinetics were obtained in all participants on Weeks 2, 4, 8, 12, 16, and 24 to obtain Bayesian estimates of TMC435 AUC24h (overall exposure).
Time Frame	Two random blood samples taken at least 2 hours apart at Weeks 2, 4, 8, 12, 16, and 24
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants who received at least 1 dose of study medication with at least 1 post-baseline pharmacokinetic (PK) assessment were included in the PK analysis population.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.

TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.

Measured Values

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**
Number of Participants Analyzed [units: participants]	**77**	**75**	**77**	**78**
Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435 [units: ng*h/mL] Median (Full Range)	**9926.4 (138 to 50179)**	**8976.8 (3615 to 57243)**	**39884.0 (2948 to 380830)**	**36038.8 (1134 to 279550)**

No statistical analysis provided for Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	72 weeks
Additional Description	All participants who received at least one dose of investigational medication included in safety analysis.

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Serious Adverse Events

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**

Total, serious adverse events					
# participants affected / at risk	**9/78 (11.54%)**	**4/75 (5.33%)**	**4/77 (5.19%)**	**3/79 (3.80%)**	**10/77 (12.99%)**
Cardiac disorders					
Myocardial infarction † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**1/77 (1.30%)**
Myopericarditis † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**1/77 (1.30%)**
Endocrine disorders					
Hyperthyroidism † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Eye disorders					
Ocular vasculitis † 1					
# participants affected / at risk	**0/78 (0.00%)**	**1/75 (1.33%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Gastrointestinal disorders					
Abdominal pain upper † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**1/79 (1.27%)**	**0/77 (0.00%)**
Colitis † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**1/77 (1.30%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Nausea † 1					
# participants affected / at risk	**0/78 (0.00%)**	**1/75 (1.33%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Small intestinal obstruction † 1					
# participants affected / at risk	**0/78 (0.00%)**	**1/75 (1.33%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Vomiting † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**1/77 (1.30%)**
General disorders					
Malaise † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**1/77 (1.30%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Asthenia † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**1/77 (1.30%)**
Hepatobiliary disorders					
Cholecystitis † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Infections and infestations					
Incision site cellulitis † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Necrotising fasciitis † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Perihepatic abscess † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**1/79 (1.27%)**	**0/77 (0.00%)**
Pneumonia pneumococcal † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Upper respiratory tract infection † 1					

# participants affected / at risk	0/78 (0.00%)	1/75 (1.33%)	0/77 (0.00%)	0/79 (0.00%)	0/77 (0.00%)
Appendicitis † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)
Subcutaneous abscess † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)
Vulval abscess † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)
Injury, poisoning and procedural complications					
Post procedural bile leak † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	1/79 (1.27%)	0/77 (0.00%)
Metabolism and nutrition disorders					
Malnutrition † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	1/77 (1.30%)	0/79 (0.00%)	0/77 (0.00%)
Type 1 diabetes mellitus † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	1/77 (1.30%)	0/79 (0.00%)	0/77 (0.00%)
Musculoskeletal and connective tissue disorders					
Intervertebral disc protrusion † 1					
# participants affected / at risk	1/78 (1.28%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	0/77 (0.00%)
Spinal disorder † 1					
# participants affected / at risk	1/78 (1.28%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	0/77 (0.00%)
Myositis † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)					
Breast cancer † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	1/77 (1.30%)	0/79 (0.00%)	0/77 (0.00%)
Parathyroid tumour benign † 1					
# participants affected / at risk	1/78 (1.28%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	0/77 (0.00%)
Ovarian neoplasm † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)
Nervous system disorders					
Headache † 1					
# participants affected / at risk	0/78 (0.00%)	1/75 (1.33%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)
Psychiatric disorders					
Depression † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	1/79 (1.27%)	0/77 (0.00%)
Respiratory, thoracic and mediastinal disorders					
Haemoptysis † 1					
# participants affected / at risk	1/78 (1.28%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	0/77 (0.00%)
Chronic obstructive pulmonary disease † 1					
# participants affected / at risk	0/78 (0.00%)	0/75 (0.00%)	0/77 (0.00%)	0/79 (0.00%)	1/77 (1.30%)

Skin and subcutaneous tissue disorders					
Cutaneous vasculitis † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**0/79 (0.00%)**	**0/77 (0.00%)**
Vascular disorders					
Hypertension † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**1/79 (1.27%)**	**0/77 (0.00%)**

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA Version 12.0

Other Adverse Events

Hide Other Adverse Events

Time Frame	72 weeks
Additional Description	All participants who received at least one dose of investigational medication included in safety analysis.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
TMC435 75 mg 12 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed by Placebo once daily and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 75 mg 24 Wks + PR 24/48	Participants received TMC435 75 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 12 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) once weekly and ribavirin (R) twice daily for 12 weeks followed Placebo and PR for 12 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
TMC435 150 mg 24 Wks + PR 24/48	Participants received TMC435 150 mg once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks. Treatment with PR was stopped at Week 24 for participants who met response-guided treatment (RGT) criteria. All other participants continued PR until Week 48.
Placebo 24 Wks + PR48	Participants received Placebo once daily with PegIFNα-2a (P) and ribavirin (R) for 24 weeks followed by PR until Week 48.

Other Adverse Events

	TMC435 75 mg 12 Wks + PR 24/48	**TMC435 75 mg 24 Wks + PR 24/48**	**TMC435 150 mg 12 Wks + PR 24/48**	**TMC435 150 mg 24 Wks + PR 24/48**	**Placebo 24 Wks + PR48**
Total, other (not including serious) adverse events					
# participants affected / at risk	**76/78 (97.44%)**	**75/75 (100.00%)**	**74/77 (96.10%)**	**77/79 (97.47%)**	**75/77 (97.40%)**
Blood and lymphatic system disorders					
Neutropenia † 1					
# participants affected /					**16/77 (20.78%)**

at risk	15/78 (19.23%)	23/75 (30.67%)	19/77 (24.68%)	18/79 (22.78%)	
Anaemia † 1					
# participants affected / at risk	15/78 (19.23%)	16/75 (21.33%)	17/77 (22.08%)	15/79 (18.99%)	16/77 (20.78%)
Leukopenia † 1					
# participants affected / at risk	2/78 (2.56%)	1/75 (1.33%)	1/77 (1.30%)	6/79 (7.59%)	4/77 (5.19%)
Ear and labyrinth disorders					
Vertigo † 1					
# participants affected / at risk	5/78 (6.41%)	1/75 (1.33%)	3/77 (3.90%)	4/79 (5.06%)	4/77 (5.19%)
Endocrine disorders					
Hypothyroidism † 1					
# participants affected / at risk	6/78 (7.69%)	1/75 (1.33%)	1/77 (1.30%)	1/79 (1.27%)	5/77 (6.49%)
Eye disorders					
Dry eye † 1					
# participants affected / at risk	3/78 (3.85%)	2/75 (2.67%)	3/77 (3.90%)	4/79 (5.06%)	4/77 (5.19%)
Vision blurred † 1					
# participants affected / at risk	3/78 (3.85%)	1/75 (1.33%)	5/77 (6.49%)	3/79 (3.80%)	1/77 (1.30%)
Gastrointestinal disorders					
Nausea † 1					
# participants affected / at risk	26/78 (33.33%)	16/75 (21.33%)	20/77 (25.97%)	24/79 (30.38%)	21/77 (27.27%)
Diarrhoea † 1					
# participants affected / at risk	12/78 (15.38%)	14/75 (18.67%)	11/77 (14.29%)	10/79 (12.66%)	12/77 (15.58%)
Vomiting † 1					
# participants affected / at risk	5/78 (6.41%)	3/75 (4.00%)	6/77 (7.79%)	8/79 (10.13%)	5/77 (6.49%)
Dry mouth † 1					
# participants affected / at risk	5/78 (6.41%)	7/75 (9.33%)	3/77 (3.90%)	6/79 (7.59%)	7/77 (9.09%)
Abdominal pain upper † 1					
# participants affected / at risk	5/78 (6.41%)	4/75 (5.33%)	6/77 (7.79%)	4/79 (5.06%)	4/77 (5.19%)
Dyspepsia † 1					
# participants affected / at risk	4/78 (5.13%)	5/75 (6.67%)	4/77 (5.19%)	6/79 (7.59%)	6/77 (7.79%)
Constipation † 1					
# participants affected / at risk	6/78 (7.69%)	1/75 (1.33%)	7/77 (9.09%)	2/79 (2.53%)	5/77 (6.49%)
Abdominal pain † 1					
# participants affected / at risk	4/78 (5.13%)	3/75 (4.00%)	4/77 (5.19%)	3/79 (3.80%)	4/77 (5.19%)
Aphthous stomatitis † 1					
# participants affected /	2/78 (2.56%)	1/75 (1.33%)	4/77 (5.19%)	2/79 (2.53%)	3/77 (3.90%)

at risk					
General disorders					
Fatigue † 1					
# participants affected / at risk	26/78 (33.33%)	35/75 (46.67%)	32/77 (41.56%)	38/79 (48.10%)	37/77 (48.05%)
Influenza like illness † 1					
# participants affected / at risk	21/78 (26.92%)	32/75 (42.67%)	18/77 (23.38%)	27/79 (34.18%)	29/77 (37.66%)
Pyrexia † 1					
# participants affected / at risk	18/78 (23.08%)	15/75 (20.00%)	15/77 (19.48%)	16/79 (20.25%)	13/77 (16.88%)
Asthenia † 1					
# participants affected / at risk	20/78 (25.64%)	12/75 (16.00%)	18/77 (23.38%)	13/79 (16.46%)	16/77 (20.78%)
Irritability † 1					
# participants affected / at risk	10/78 (12.82%)	7/75 (9.33%)	14/77 (18.18%)	11/79 (13.92%)	8/77 (10.39%)
Chills † 1					
# participants affected / at risk	4/78 (5.13%)	8/75 (10.67%)	6/77 (7.79%)	7/79 (8.86%)	8/77 (10.39%)
Injection site erythema † 1					
# participants affected / at risk	4/78 (5.13%)	8/75 (10.67%)	5/77 (6.49%)	7/79 (8.86%)	4/77 (5.19%)
Injection site reaction † 1					
# participants affected / at risk	5/78 (6.41%)	4/75 (5.33%)	2/77 (2.60%)	2/79 (2.53%)	4/77 (5.19%)
Pain † 1					
# participants affected / at risk	6/78 (7.69%)	2/75 (2.67%)	2/77 (2.60%)	1/79 (1.27%)	2/77 (2.60%)
Hepatobiliary disorders					
Hyperbilirubinaemia † 1					
# participants affected / at risk	2/78 (2.56%)	0/75 (0.00%)	5/77 (6.49%)	2/79 (2.53%)	2/77 (2.60%)
Infections and infestations					
Nasopharyngitis † 1					
# participants affected / at risk	1/78 (1.28%)	5/75 (6.67%)	4/77 (5.19%)	4/79 (5.06%)	6/77 (7.79%)
Influenza † 1					
# participants affected / at risk	1/78 (1.28%)	5/75 (6.67%)	4/77 (5.19%)	3/79 (3.80%)	3/77 (3.90%)
Urinary tract infection † 1					
# participants affected / at risk	2/78 (2.56%)	2/75 (2.67%)	1/77 (1.30%)	5/79 (6.33%)	2/77 (2.60%)
Sinusitis † 1					
# participants affected / at risk	4/78 (5.13%)	0/75 (0.00%)	1/77 (1.30%)	2/79 (2.53%)	2/77 (2.60%)
Investigations					
Weight decreased † 1					
# participants affected / at risk	7/78 (8.97%)	3/75 (4.00%)	3/77 (3.90%)	6/79 (7.59%)	3/77 (3.90%)

Neutrophil count decreased † 1					
# participants affected / at risk	**1/78 (1.28%)**	**5/75 (6.67%)**	**5/77 (6.49%)**	**4/79 (5.06%)**	**4/77 (5.19%)**
Blood bilirubin increased † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**5/77 (6.49%)**	**5/79 (6.33%)**	**0/77 (0.00%)**
Alanine aminotransferase increased † 1					
# participants affected / at risk	**3/78 (3.85%)**	**1/75 (1.33%)**	**1/77 (1.30%)**	**5/79 (6.33%)**	**0/77 (0.00%)**
Aspartate aminotransferase increased † 1					
# participants affected / at risk	**2/78 (2.56%)**	**1/75 (1.33%)**	**1/77 (1.30%)**	**6/79 (7.59%)**	**0/77 (0.00%)**
Gamma-glutamyltransferase increased † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**0/77 (0.00%)**	**4/79 (5.06%)**	**0/77 (0.00%)**
Metabolism and nutrition disorders					
Anorexia † 1					
# participants affected / at risk	**10/78 (12.82%)**	**12/75 (16.00%)**	**11/77 (14.29%)**	**9/79 (11.39%)**	**11/77 (14.29%)**
Decreased appetite † 1					
# participants affected / at risk	**6/78 (7.69%)**	**3/75 (4.00%)**	**4/77 (5.19%)**	**4/79 (5.06%)**	**6/77 (7.79%)**
Musculoskeletal and connective tissue disorders					
Myalgia † 1					
# participants affected / at risk	**17/78 (21.79%)**	**12/75 (16.00%)**	**16/77 (20.78%)**	**10/79 (12.66%)**	**17/77 (22.08%)**
Arthralgia † 1					
# participants affected / at risk	**11/78 (14.10%)**	**12/75 (16.00%)**	**14/77 (18.18%)**	**16/79 (20.25%)**	**11/77 (14.29%)**
Back pain † 1					
# participants affected / at risk	**5/78 (6.41%)**	**8/75 (10.67%)**	**10/77 (12.99%)**	**7/79 (8.86%)**	**7/77 (9.09%)**
Muscle spasms † 1					
# participants affected / at risk	**4/78 (5.13%)**	**2/75 (2.67%)**	**1/77 (1.30%)**	**4/79 (5.06%)**	**4/77 (5.19%)**
Musculoskeletal pain † 1					
# participants affected / at risk	**1/78 (1.28%)**	**4/75 (5.33%)**	**0/77 (0.00%)**	**3/79 (3.80%)**	**6/77 (7.79%)**
Pain in extremity † 1					
# participants affected / at risk	**1/78 (1.28%)**	**1/75 (1.33%)**	**1/77 (1.30%)**	**3/79 (3.80%)**	**5/77 (6.49%)**
Nervous system disorders					

Headache † 1					
# participants affected / at risk	**41/78 (52.56%)**	**34/75 (45.33%)**	**35/77 (45.45%)**	**32/79 (40.51%)**	**40/77 (51.95%)**
Dizziness † 1					
# participants affected / at risk	**10/78 (12.82%)**	**3/75 (4.00%)**	**4/77 (5.19%)**	**12/79 (15.19%)**	**6/77 (7.79%)**
Disturbance in attention † 1					
# participants affected / at risk	**5/78 (6.41%)**	**3/75 (4.00%)**	**6/77 (7.79%)**	**4/79 (5.06%)**	**3/77 (3.90%)**
Dysgeusia † 1					
# participants affected / at risk	**6/78 (7.69%)**	**1/75 (1.33%)**	**5/77 (6.49%)**	**4/79 (5.06%)**	**5/77 (6.49%)**
Paraesthesia † 1					
# participants affected / at risk	**1/78 (1.28%)**	**0/75 (0.00%)**	**4/77 (5.19%)**	**1/79 (1.27%)**	**1/77 (1.30%)**
Syncope † 1					
# participants affected / at risk	**1/78 (1.28%)**	**2/75 (2.67%)**	**2/77 (2.60%)**	**1/79 (1.27%)**	**4/77 (5.19%)**
Migraine † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**1/77 (1.30%)**	**4/79 (5.06%)**	**0/77 (0.00%)**
Hypoaesthesia † 1					
# participants affected / at risk	**0/78 (0.00%)**	**0/75 (0.00%)**	**1/77 (1.30%)**	**1/79 (1.27%)**	**4/77 (5.19%)**
Psychiatric disorders					
Insomnia † 1					
# participants affected / at risk	**19/78 (24.36%)**	**14/75 (18.67%)**	**23/77 (29.87%)**	**13/79 (16.46%)**	**23/77 (29.87%)**
Depression † 1					
# participants affected / at risk	**8/78 (10.26%)**	**4/75 (5.33%)**	**9/77 (11.69%)**	**11/79 (13.92%)**	**14/77 (18.18%)**
Sleep disorder † 1					
# participants affected / at risk	**8/78 (10.26%)**	**3/75 (4.00%)**	**4/77 (5.19%)**	**7/79 (8.86%)**	**4/77 (5.19%)**
Mood altered † 1					
# participants affected / at risk	**4/78 (5.13%)**	**5/75 (6.67%)**	**1/77 (1.30%)**	**8/79 (10.13%)**	**7/77 (9.09%)**
Depressed mood † 1					
# participants affected / at risk	**4/78 (5.13%)**	**4/75 (5.33%)**	**3/77 (3.90%)**	**6/79 (7.59%)**	**3/77 (3.90%)**
Anxiety † 1					
# participants affected / at risk	**5/78 (6.41%)**	**2/75 (2.67%)**	**4/77 (5.19%)**	**4/79 (5.06%)**	**5/77 (6.49%)**
Mood swings † 1					
# participants affected / at risk	**4/78 (5.13%)**	**0/75 (0.00%)**	**1/77 (1.30%)**	**5/79 (6.33%)**	**3/77 (3.90%)**
Respiratory, thoracic and mediastinal disorders					
Cough † 1					
# participants affected /	**18/78 (23.08%)**	**9/75 (12.00%)**	**12/77 (15.58%)**	**13/79 (16.46%)**	**15/77 (19.48%)**

at risk					
Dyspnoea † [1]					
# participants affected / at risk	12/78 (15.38%)	8/75 (10.67%)	7/77 (9.09%)	6/79 (7.59%)	6/77 (7.79%)
Dyspnoea exertional † [1]					
# participants affected / at risk	6/78 (7.69%)	9/75 (12.00%)	10/77 (12.99%)	5/79 (6.33%)	7/77 (9.09%)
Oropharyngeal pain † [1]					
# participants affected / at risk	5/78 (6.41%)	3/75 (4.00%)	4/77 (5.19%)	4/79 (5.06%)	8/77 (10.39%)
Skin and subcutaneous tissue disorders					
Pruritus † [1]					
# participants affected / at risk	25/78 (32.05%)	17/75 (22.67%)	30/77 (38.96%)	24/79 (30.38%)	35/77 (45.45%)
Rash † [1]					
# participants affected / at risk	21/78 (26.92%)	10/75 (13.33%)	16/77 (20.78%)	18/79 (22.78%)	18/77 (23.38%)
Dry skin † [1]					
# participants affected / at risk	12/78 (15.38%)	12/75 (16.00%)	17/77 (22.08%)	22/79 (27.85%)	14/77 (18.18%)
Alopecia † [1]					
# participants affected / at risk	20/78 (25.64%)	11/75 (14.67%)	11/77 (14.29%)	11/79 (13.92%)	16/77 (20.78%)
Erythema † [1]					
# participants affected / at risk	3/78 (3.85%)	2/75 (2.67%)	5/77 (6.49%)	5/79 (6.33%)	4/77 (5.19%)
Eczema † [1]					
# participants affected / at risk	7/78 (8.97%)	1/75 (1.33%)	3/77 (3.90%)	3/79 (3.80%)	5/77 (6.49%)
Pruritus generalised † [1]					
# participants affected / at risk	3/78 (3.85%)	2/75 (2.67%)	3/77 (3.90%)	6/79 (7.59%)	5/77 (6.49%)
Night sweats † [1]					
# participants affected / at risk	6/78 (7.69%)	1/75 (1.33%)	1/77 (1.30%)	2/79 (2.53%)	1/77 (1.30%)
Dermatitis † [1]					
# participants affected / at risk	1/78 (1.28%)	4/75 (5.33%)	1/77 (1.30%)	1/79 (1.27%)	1/77 (1.30%)
Hyperhidrosis † [1]					
# participants affected / at risk	1/78 (1.28%)	3/75 (4.00%)	0/77 (0.00%)	3/79 (3.80%)	4/77 (5.19%)
Vascular disorders					
Hot flush † [1]					
# participants affected / at risk	1/78 (1.28%)	0/75 (0.00%)	2/77 (2.60%)	5/79 (6.33%)	2/77 (2.60%)
Hypertension † [1]					
# participants affected / at risk	0/78 (0.00%)	1/75 (1.33%)	1/77 (1.30%)	4/79 (5.06%)	2/77 (2.60%)

† Events were collected by systematic assessment

1 Term from vocabulary, MedDRA Version 12.0

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are **NOT** employed by the organization sponsoring the study.
There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is: ☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo. ☑ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo. ☐ Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Results Point of Contact:

Name/Title: Global Clinical Development Manager
Organization: Jan-Cil France
e-mail: ClinicalTrialDisclosure@its.jnj.com

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M, Buelens A, Ceulemans H, Beumont M, Picchio G, De Meyer S. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. J Hepatol. 2015 May;62(5):1008-14. doi: 10.1016/j.jhep.2014.11.032. Epub 2014 Nov 28.

Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013 Dec;58(6):1918-29. doi: 10.1002/hep.26641. Epub 2013 Oct 11.

Responsible Party:	Tibotec Pharmaceuticals, Ireland
ClinicalTrials.gov Identifier:	NCT00882908 History of Changes
Other Study ID Numbers:	CR015799 **TMC435-TiDP16-C205** (Other Identifier: Tibotec Pharmaceuticals, Ireland) 2008-007147-13 (EudraCT Number)
Study First Received:	April 16, 2009
Results First Received:	December 18, 2013
Last Updated:	May 19, 2014
Health Authority:	United States: Food and Drug Administration Canada: Health Canada Portugal: National Pharmacy and Medicines Institute Australia: Department of Health and Ageing Therapeutic Goods Administration

Austria: Federal Office for Safety in Health Care
Belgium: Federal Agency for Medicinal Products and Health Products
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Israel: Ministry of Health
New Zealand: Medsafe
Norway: Norwegian Medicines Agency
Poland: The Central Register of Clinical Trials
Russia: Ministry of Health of the Russian Federation
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Disclaimer

Information in this posting shall not be considered to be a claim for any marketed Product. Some information in this posting may differ from the approved labeling for the Product. Please refer to the full prescribing information for indications and proper use of the product.